
Chronic Pulmonary Aspergillosis (CPA) is often described as a long-term condition, but people sometimes wonder why it isn’t called a “lifelong” disease — especially since many people need antifungal treatment and regular monitoring for years.
Here’s what we know:
🩺 CPA Affects Everyone Differently
CPA is a complex condition that includes several forms — some people have a single fungal ball (aspergilloma), while others have more widespread or progressive disease. For many, CPA needs long-term treatment, such as antifungal tablets, oxygen, physiotherapy, or hospital care.
But not everyone has the same experience:
-
Some people are stable for years
-
Some respond well to treatment and no longer need antifungals
-
Others may live with occasional flare-ups or long-term health problems
🔁 Why It’s Not Always Called Lifelong
CPA is called a “long-term condition” because:
-
It typically lasts at least a year, often longer
-
It may come and go in phases
-
It needs regular follow-up and may affect daily life
But not everyone will have it for the rest of their life — and that’s why we don’t use the word “lifelong” for everyone.
🔬 We Don’t Yet Know Who is Truly ‘Cured’
To say whether CPA is curable, we would need to:
-
Follow a large group of patients
-
For many decades
-
To see who stays well and never relapses
That kind of long-term research is still ongoing — so at the moment, doctors can’t say for sure when or if someone is permanently cured.
Some people stay well for years after stopping treatment — but it’s too early to know if the infection is truly gone, or just sleeping.
💬 What This Means for You
-
CPA is a condition that can be managed — sometimes very successfully
-
You might not need treatment forever — but regular check-ups help catch any changes early
-
Your team will work with you to find the right balance of treatment and independence
-
If you feel well, that’s a good sign — but it’s still important to keep an eye on things
📍In short: CPA is a serious, long-term condition, but it’s not always lifelong. We still have more to learn, and long-term studies are helping us understand it better every year.
Share this post
Latest News posts
Nontuberculous Mycobacteria (NTM–MAC) and Aspergillosis
March 10, 2026
Asthma and Aspergillosis
March 9, 2026
Weekly Aspergillosis Research Update – Week 10, 2026
March 9, 2026
Bronchiectasis in Aspergillosis Patients
March 6, 2026
Damp & Mould Health Evidence Monitor: 4 March 2026
March 4, 2026
Weeks 6–7 Aspergillosis Literature Update
March 3, 2026
News archive
- ABPA
- Air Quality
- Airway Clearance, Diagnosis & Physiotherapy
- Antifungals
- Aspergilloma
- Aspergillus Bronchitis
- Biologics
- Blood Tests
- CPA
- Carers & Family
- Communities
- Complementary & Supplements
- Complications
- Conditions
- Diagnostics
- Environment
- Events & Recordings
- GP Guidance
- General interest
- Housing & Damp
- Imaging
- Immune System
- Lifestyle & Coping
- Living with Aspergillosis
- Mental Health
- Monitoring
- Monitoring & Safety
- NAC & Guidance
- NAC Announcements
- Other
- Other Forms Aspergillosis
- Patient Research
- Pets & Animals
- Professional Guidance
- Recordings
- Research
- Research Summaries
- SAFS / Severe Asthma
- Side Effects
- Specialists
- Steroids
- Symptoms
- Travel and Insurance
- Treatment
- Vaccines
- Weekly Updates
